Howard Schiller, the interim CEO of Valeant Pharmaceuticals International Inc. in January and February, appeared before the House Committee on Oversight and Government Reform on Feb. 4. long a darling among mutual funds, took a terrible hit from its heavy concentration in one stock, Valeant Pharmaceuticals International Inc. Here's how the fund and Valeant's stock have performed over the past year against the benchmark the S&P 500 Jaffe took a hard look at the dysfunctional management culture at Sequoia that led to such a risky bet and the fund's subsequent fall from grace.